STOCK TITAN

COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

COSCIENS Biopharma (NASDAQ: CSCI; TSX: CSCI), a life sciences company focused on cosmeceutical, nutraceutical and pharmaceutical products, has announced the results of its virtual annual general and special meeting of shareholders (AGSM).

All six directors were successfully elected to the board, with most nominees receiving over 88% approval, except for Ronald W. Miller who received 68.75% of votes in favor. The shareholders also approved the appointment of Deloitte LLP as the company's auditor and passed a resolution approving the Amended and Restated Shareholder Rights Plan.

As an Eligible Interlisted Issuer on the TSX, COSCIENS obtained an exemption from certain Canadian requirements regarding its long-term incentive plan, eliminating the need for shareholder approval of unallocated entitlements at the AGSM.

COSCIENS Biopharma (NASDAQ: CSCI; TSX: CSCI), un'azienda nel settore delle scienze della vita specializzata in prodotti cosmeceutici, nutraceutici e farmaceutici, ha annunciato i risultati della sua assemblea annuale virtuale ordinaria e straordinaria degli azionisti (AGSM).

Tutti e sei i direttori sono stati eletti con successo nel consiglio di amministrazione, con la maggior parte dei candidati che ha ottenuto un 88% di approvazione, ad eccezione di Ronald W. Miller che ha ricevuto il 68,75% dei voti favorevoli. Gli azionisti hanno inoltre approvato la nomina di Deloitte LLP come revisore dei conti della società e hanno approvato una risoluzione relativa al Piano dei Diritti degli Azionisti emendato e riformulato.

In qualità di Emittente Interlistata Idonea sulla TSX, COSCIENS ha ottenuto un'esenzione da alcuni requisiti canadesi riguardanti il suo piano di incentivi a lungo termine, eliminando la necessità di approvazione da parte degli azionisti per le assegnazioni non allocate durante l'AGSM.

COSCIENS Biopharma (NASDAQ: CSCI; TSX: CSCI), una empresa de ciencias de la vida enfocada en productos cosmecéuticos, nutracéuticos y farmacéuticos, ha anunciado los resultados de su reunión anual virtual ordinaria y extraordinaria de accionistas (AGSM).

Los seis directores fueron elegidos con éxito para la junta, con la mayoría de los candidatos recibiendo más del 88% de aprobación, excepto Ronald W. Miller, quien obtuvo el 68.75% de los votos a favor. Los accionistas también aprobaron el nombramiento de Deloitte LLP como auditor de la empresa y aprobaron una resolución que ratifica el Plan de Derechos de los Accionistas enmendado y reformulado.

Como Emisor Elegible Interlistado en la TSX, COSCIENS obtuvo una exención de ciertos requisitos canadienses relacionados con su plan de incentivos a largo plazo, eliminando la necesidad de aprobación de los accionistas para las asignaciones no asignadas en la AGSM.

COSCIENS Biopharma (NASDAQ: CSCI; TSX: CSCI)는 코스메슈티컬, 뉴트라슈티컬 및 제약 제품에 중점을 둔 생명 과학 회사로서, 주주들의 가상 연례 일반 및 특별 총회(AGSM) 결과를 발표했습니다.

여섯 명의 이사가 모두 이사회에 성공적으로 선출되었으며, 대부분의 후보자는 88% 이상의 찬성표를 받았으나 Ronald W. Miller는 68.75%의 찬성표를 받았습니다. 주주들은 또한 회사의 감사인으로 Deloitte LLP의 선임을 승인하고, 수정 및 재작성된 주주 권리 계획에 대한 결의안을 통과시켰습니다.

TSX의 적격 상호 상장 발행인으로서 COSCIENS는 장기 인센티브 계획과 관련된 일부 캐나다 요구사항에 대한 면제를 받아, AGSM에서 미할당 권리의 주주 승인 필요성을 없앴습니다.

COSCIENS Biopharma (NASDAQ : CSCI ; TSX : CSCI), une entreprise des sciences de la vie spécialisée dans les produits cosmétopharmaceutiques, nutraceutiques et pharmaceutiques, a annoncé les résultats de son assemblée générale annuelle virtuelle ordinaire et extraordinaire des actionnaires (AGSM).

Tous les six administrateurs ont été élus avec succès au conseil d'administration, la plupart des candidats ayant obtenu plus de 88 % d'approbation, à l'exception de Ronald W. Miller qui a reçu 68,75 % des voix favorables. Les actionnaires ont également approuvé la nomination de Deloitte LLP en tant que commissaire aux comptes de la société et adopté une résolution approuvant le plan modifié et reformulé des droits des actionnaires.

En tant qu'émetteur intercoté éligible à la TSX, COSCIENS a obtenu une exemption de certaines exigences canadiennes relatives à son plan d'incitation à long terme, éliminant ainsi la nécessité d'une approbation des actionnaires pour les droits non attribués lors de l'AGSM.

COSCIENS Biopharma (NASDAQ: CSCI; TSX: CSCI), ein Life-Sciences-Unternehmen mit Fokus auf kosmetisch-pharmazeutische, nutraceutical und pharmazeutische Produkte, hat die Ergebnisse seiner virtuellen jährlichen ordentlichen und außerordentlichen Hauptversammlung der Aktionäre (AGSM) bekannt gegeben.

Alle sechs Direktoren wurden erfolgreich in den Vorstand gewählt, wobei die meisten Kandidaten über 88% Zustimmung erhielten, mit Ausnahme von Ronald W. Miller, der 68,75% der Stimmen erhielt. Die Aktionäre genehmigten außerdem die Ernennung von Deloitte LLP als Wirtschaftsprüfer des Unternehmens und verabschiedeten eine Resolution zur Genehmigung des geänderten und neu formulierten Aktionärsrechtsplans.

Als berechtigter, an der TSX notierter Emittent erhielt COSCIENS eine Befreiung von bestimmten kanadischen Anforderungen bezüglich seines langfristigen Anreizplans, wodurch die Zustimmung der Aktionäre für nicht zugewiesene Ansprüche bei der AGSM entfiel.

Positive
  • None.
Negative
  • Director Ronald W. Miller received significantly lower approval at 68.75% with 31.25% votes against

TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the “AGSM”) held today.

Results of the AGSM

The results of the vote in respect of the election of directors of the Company are set out below:

Name of Nominee Votes For  % For  Votes Against  % Against 
Peter H. Puccetti (Chair)  580,289   88.92%  72,286   11.08%
Anthony J. Giovinazzo  574,954   88.11%  77,621   11.89%
Ulrich Kosciessa  580,140   88.90%  72,435   11.10%
Ronald W. Miller  448,646   68.75%  203,929   31.25%
Robert A. Seager  580,254   88.92%  72,321   11.08%
David Spear  580,106   88.89%  72,469   11.11%

In addition, at the AGSM, Deloitte LLP was appointed as the Company’s auditor, and an ordinary resolution re-confirming and approving the Company’s Amended and Restated Shareholder Rights Plan (as described in the management information circular circulated in connection with the AGSM dated June 3, 2025) was approved.

The Company is an “Eligible Interlisted Issuer” as such term is defined in the TSX Company Manual. As an Eligible Interlisted Issuer, the Company has relied on an exemption pursuant to Section 602.1 of the TSX Company Manual from Section 613 of the TSX Company Manual, the effect of which is that, subject to the satisfaction of certain conditions prescribed by the Toronto Stock Exchange, the Company will not have to comply with certain Canadian requirements in connection with the Company’s long-term incentive plan (the “Exemption”). As a result, shareholders were not asked to approve the unallocated entitlements under the Company’s long-term incentive plan at the AGSM.

For full voting details, please see the report of voting results filed on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov.
  
About COSCIENS Biopharma Inc.

COSCIENS is a life sciences company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products. Our technology includes proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products (i.e., oat beta glucan and avenanthramides which are found in leading skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals. Our consolidated portfolio also includes macimorelin (Macrilen®; Ghryvelin®), the first and only U.S. FDA and European Medicines Agency approved oral test indicated for the diagnosis of adult growth hormone deficiency (“AGHD”).

The Company is listed on the NASDAQ Capital Market and the Toronto Stock Exchange, and trades on both exchanges under the ticker symbol “CSCI”. For more information, please visit COSCIENS’ website at www.cosciensbio.com.

Forward-Looking Statements

Certain statements in this news release, referred to herein as “forward-looking statements”, constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and “forward-looking information” under the provisions of Canadian securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this news release, words such as “anticipate”, “assume”, “believe”, “could”, “expect”, “forecast”, “future”, “goal”, “guidance”, “intend”, “likely”, “may”, “would” or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words. Forward-looking statements in this news release include, but are not limited to, statements relating to the satisfaction of Toronto Stock Exchange conditions related to the Company’s reliance on the Exemption.

Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by the Company as of the date of such statements, are inherently subject to significant business, economic, operational and other risks, uncertainties, contingencies and other factors, including those described below, which could cause actual results, performance or achievements of the combined Company to be materially different from results, performance or achievements expressed or implied by such forward-looking statements and, as such, undue reliance must not be placed on them.

Forward-looking statements involve known and unknown risks and uncertainties which include, among others: the combined Company’s present and future business strategies; operations and performance within expected ranges; anticipated future cash flows; local and global economic conditions and the environment in which the combined Company operates; anticipated capital and operating costs; uncertainty in our revenue generation from our marketed products, product development and related clinical trials and validation studies; results from our products under development may not be successful or may not support advancing the product; the failure of the DETECT-trial to achieve its primary endpoint in children (CGHD) may impact the market for macimorelin (Macrilen®; Ghryvelin®) in adults (AGHD) and the existing relationships we have for that product; ability to raise capital and obtain financing to continue our currently planned operations; our now heavy dependence on sales by and revenue from our main distributor of our legacy Ceapro products and its customers, the continued availability of funds and resources to successfully commercialize our products; the ability to secure strategic partners for late stage development, marketing, and distribution of our products; our ability to enter into out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our ability to protect and enforce our patent portfolio and intellectual property; and our ability to continue to list our common shares on the NASDAQ Capital Market. Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties, including those discussed in our Annual Report on Form 20-F and MD&A filed under the Company’s profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. We disclaim any obligation to update any such risks or uncertainties or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this news release.

Issuer:

Anna Biehn
Chief Executive Officer
E: ABiehn@cosciensbio.com 


FAQ

What were the voting results for COSCIENS Biopharma (CSCI) directors at the 2025 AGSM?

Five directors received over 88% approval votes, while Ronald W. Miller received 68.75% approval with 31.25% votes against.

Who was appointed as COSCIENS Biopharma's (CSCI) auditor in 2025?

Deloitte LLP was appointed as the company's auditor at the 2025 annual general and special meeting.

What is COSCIENS Biopharma's (CSCI) Eligible Interlisted Issuer status?

As an Eligible Interlisted Issuer on the TSX, COSCIENS received an exemption from certain Canadian requirements regarding its long-term incentive plan approval.

What resolutions were approved at COSCIENS (CSCI) 2025 shareholder meeting?

Shareholders approved the election of directors, appointment of Deloitte LLP as auditor, and the Amended and Restated Shareholder Rights Plan.
Cosciens Biopharma

NASDAQ:CSCI

CSCI Rankings

CSCI Latest News

CSCI Latest SEC Filings

CSCI Stock Data

10.61M
3.10M
1.29%
7.38%
0.36%
Biotechnology
Healthcare
Link
Canada
Toronto